

# FSD Pharma

I ? . Ž ( ( f \$ L & \$ + ' - , - ' \$ , %  
 B 5 . Ž % \* ( \* ; - \* ' \$ \* )  
 5 1 Ž \* % & ' - & , \$ \$ + \$ \$  
 U W j c b 4 d f c U W j Y j b j Y g h c f g " V e a

09:40 30 Jul 2020

## FSD Pharma notifies Health Canada it will forfeit licenses of subsidiary FV Pharma and suspend operations

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) has notified Health Canada it will forfeit the licenses of its wholly-owned subsidiary FV Pharma Inc and suspend all activities within 30 days of the notification date.

In a statement Thursday, the company said it has begun the process of liquidating all FV Pharma assets, including the sale of the company's medical cannabis production facility in Cobourg, Ontario.

CEO Dr Raza Bokhari said the decision to shutter the subsidiary is in the best interests of shareholders as the company now focuses on advancing its lead compound FSD201 to treat hospitalized coronavirus (COVID-19) patients and expanding its overall drug pipeline.

### READ: FSD Pharma announces US\$20M offering to help fund research on lead drug candidate FSD-201

Bokhari said the company is actively working to submit an Investigational New Drug Application (IND) to the US Food and Drug Administration to use FSD201 as a way to reduce lung inflation caused by small proteins called cytokines that are central to the "cytokine storm" phenomenon, where the body starts to attack its own cells rather than just fighting off the SARS-CoV-2 virus.

"We are hopeful to initiate the Phase 2 clinical trial before the end of this year and remain cautiously optimistic that our study may improve treatment outcome for COVID-19 patients," he said.

FSD Pharma said it is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 coronavirus) at this time.

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

**Price:** 2.63

**Market Cap:** \$50.4 m

### 1 Year Share Price Graph



January 2020 July 2020 January 2021

### Share Information

**Code:** HUGE

**Listing:** CSE

**52 week High Low**  
14.74 1.7

**Sector:** Pharma & Biotech

**Website:** [fsdpharma.com](http://fsdpharma.com)

### Company Synopsis:

FSD Pharma Inc. is a publicly-traded holding company, since May 2018. FSD Pharma BioSciences, Inc. , a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, ultramicrosized-palmitoylethanolamide ("FSD201"), by down-regulating the cytokines to effectuate an anti-inflammatory response.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).